MedTrace Logo

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer

NCT05913570 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-06-22

No results posted yet for this study

Summary

This study will evaluate the safety, and tolerability of Cadonilimab as neoadjuvant treatment for resectable local advanced colorectal cancer patient with dMMR/MSI-H.

Conditions

  • Colorectal Cancer
  • Mismatch Repair-deficient (dMMR)
  • Microsatellite Instability-high (MSI-H)
  • Neoadjuvant Therapy

Interventions

DRUG

Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody

10mg/kg, Q3W for 4 cycles

Sponsors & Collaborators

  • LiuYing

    lead OTHER_GOV

Principal Investigators

  • Ying Liu, MD · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2023-12-20
Completion
2023-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05913570 on ClinicalTrials.gov